Presentation is loading. Please wait.

Presentation is loading. Please wait.

An isogenic cell line screen reveals genomic drivers of drug response.

Published byIvan Salim Modified over 5 years ago

Similar presentations

Presentation on theme: "An isogenic cell line screen reveals genomic drivers of drug response."— Presentation transcript:

1 An isogenic cell line screen reveals genomic drivers of drug response.
An isogenic cell line screen reveals genomic drivers of drug response. A, overview of screening approach in MCF10A isogenic cell lines. For each isogenic line, relative drug responses are comparing empty vector expressing MCF10A cells exposed to the same drugs. B, pie chart depicting FDA approval status of 90 compounds in this study. C, distribution of drugs targeting distinct cancer pathways and particular kinase targets (inset). D, volcano plot comparing magnitude and significance score of altered drug responses as compared against control MCF10A parental cells for 4,541 chemical–genetic interactions interrogated in this study. Maximum FDR rates of score ranges are indicated (see Methods). Data points reflecting resistance compared with control of HRAS/KRAS/NRAS G12V-mutant MCF10A cells to EGFR inhibitors erlotinib and vandetanib are highlighted. E, the 51 genes analyzed in this study are sorted on the basis of the number of high scoring chemical interactions (number of interactions with |S| > 4 or |S| > 2). Maria M. Martins et al. Cancer Discov 2015;5: ©2015 by American Association for Cancer Research

Download ppt "An isogenic cell line screen reveals genomic drivers of drug response."

Similar presentations

Samsung Genome Institute Samsung Medical Center

Samsung Genome Institute Samsung Medical Center
Network protein vulnerability in EGFR TKI‐resistant cells and specific for EGFR‐mutated cells. Network protein vulnerability in EGFR TKI‐resistant cells.

Network protein vulnerability in EGFR TKI‐resistant cells and specific for EGFR‐mutated cells. Network protein vulnerability in EGFR TKI‐resistant cells.
The cBio Cancer Genomics Portal.

The cBio Cancer Genomics Portal.
Clonal evolution of resistance to sequential ALK inhibitor therapy.

Clonal evolution of resistance to sequential ALK inhibitor therapy.
Carlos L. Arteaga, Jeffrey A. Engelman  Cancer Cell 

Carlos L. Arteaga, Jeffrey A. Engelman  Cancer Cell 
Genetic alterations in the PI3K–PTEN–AKT pathway detected during disease progression and their functional impacts. Genetic alterations in the PI3K–PTEN–AKT.

Genetic alterations in the PI3K–PTEN–AKT pathway detected during disease progression and their functional impacts. Genetic alterations in the PI3K–PTEN–AKT.
High-throughput drug screen and validation to nominate patient-specific therapeutic options. High-throughput drug screen and validation to nominate patient-specific.

High-throughput drug screen and validation to nominate patient-specific therapeutic options. High-throughput drug screen and validation to nominate patient-specific.
WES detects a limited number of clinically targetable alterations in patients with advanced cancer. WES detects a limited number of clinically targetable.

WES detects a limited number of clinically targetable alterations in patients with advanced cancer. WES detects a limited number of clinically targetable.
HIS-24 regulates expression of infection-inducible genes.

HIS-24 regulates expression of infection-inducible genes.
Fig. 8. Gene and protein changes in ALK-dependent STING pathways in human sepsis. Gene and protein changes in ALK-dependent STING pathways in human sepsis.

Fig. 8. Gene and protein changes in ALK-dependent STING pathways in human sepsis. Gene and protein changes in ALK-dependent STING pathways in human sepsis.
Genome-Wide Analysis of PLT2 Binding to Target Genes.

Genome-Wide Analysis of PLT2 Binding to Target Genes.
AKT dependence of ovarian cancer cell lines.

AKT dependence of ovarian cancer cell lines.
ASSIGNMENT 10 Use the UP and DOWN tags as provided and query the LINCS. These are the KRAS-DEP (UP) and KRAS-IND (DOWN) gene signatures from Singh et al.

ASSIGNMENT 10 Use the UP and DOWN tags as provided and query the LINCS. These are the KRAS-DEP (UP) and KRAS-IND (DOWN) gene signatures from Singh et al.
Identification of TLOC1 and SKIL as tumor driver genes in 3q26.

Identification of TLOC1 and SKIL as tumor driver genes in 3q26.
SgRNAs targeting the 5′ coding region of β-catenin are ineffective due to an alternative translation initiation site in exon 3. sgRNAs targeting the 5′

SgRNAs targeting the 5′ coding region of β-catenin are ineffective due to an alternative translation initiation site in exon 3. sgRNAs targeting the 5′
Figure 1. A CRISPR/Cas9 synthetic lethal screen with PRMT5 inhibitor EPZ015666 in H2171 cell line. (A) A pie chart ... Figure 1. A CRISPR/Cas9 synthetic.

Figure 1. A CRISPR/Cas9 synthetic lethal screen with PRMT5 inhibitor EPZ in H2171 cell line. (A) A pie chart ... Figure 1. A CRISPR/Cas9 synthetic.
High-throughput combination drug screening to nominate potent drug combinations. High-throughput combination drug screening to nominate potent drug combinations.

High-throughput combination drug screening to nominate potent drug combinations. High-throughput combination drug screening to nominate potent drug combinations.
Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines

Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines
Chromosome 8 cDNA microarray gene expression profile of the amplified regions of 8p11–12 in SUM-44, -52, and -225 cells versus MCF10A HME control cells.

Chromosome 8 cDNA microarray gene expression profile of the amplified regions of 8p11–12 in SUM-44, -52, and -225 cells versus MCF10A HME control cells.
A genome-wide RNAi pooled screen identifies NF1 as a key determinant of RAF inhibitor sensitivity in melanoma cells. A genome-wide RNAi pooled screen identifies.

A genome-wide RNAi pooled screen identifies NF1 as a key determinant of RAF inhibitor sensitivity in melanoma cells. A genome-wide RNAi pooled screen identifies.

Similar presentations

Ads by Google